Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals

Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.

from Reuters: Health News https://ift.tt/32ofZwk
via IFTTT